TY - JOUR
T1 - Establishment of human acute myelogenous leukemia lines secreting interleukin-1β in SCID mice
AU - Giavazzi, R.
AU - Di Berardino, C.
AU - Garofalo, A.
AU - Motta, T.
AU - Gobbi, A.
AU - Scanziani, E.
AU - Giudici, G.
AU - Galli, M.
AU - Mayo, J. G.
AU - Barbui, T.
AU - Biondi, A.
AU - Rambaldi, A.
PY - 1995
Y1 - 1995
N2 - A reproducible in vivo model of human acute myelogeneous leukemia (AML) was established in severe combined immunodeficient (SCID) mice. The AML-CL and AML-PS lines were originated from leukemic blasts purified respectively from the peripheral blood of a 27-year-old woman with previously untreated hyperleukocytotic AML and from the bone marrow of a 61-year-old man during the third leukemic relapse. The 2 lines were maintained and serially transplanted i.p. in SCID mice. AML-PS and AML-CL produced ascitogenous gross tumors after approximately 4 and 6 weeks, respectively, and all mice died within 6-8 weeks. Microscopic evaluation of different organs at autopsy showed massive involvement of bone marrow, liver and spleen, though with differences in the tumor burdens for the 2 lines (AML-CL > AML-PS). Flow cytometric analysis documented the spread of leukemic cells to bone marrow, peripheral blood and spleen. AML-PS and AML-CL cells show an immunophenotypic profile (CD13+, CD33+) and cytogenetic findings similar to freshly isolated blasts. Interleukin-1β (IL-1β) gene expression was observed by Northern blot analysis in leukemic cells from AML-CL and AML-PS SCID mice. After 24 hr of culture both lines released IL-1β in culture supernatants. High levels of circulating IL-1β were secreted in plasma of tumor-bearing mice. This AML-SCID murine model could contribute to an understanding of the mechanisms of AML growth in vivo and the possible role of the autocrine production of IL-1β in promoting cell growth.
AB - A reproducible in vivo model of human acute myelogeneous leukemia (AML) was established in severe combined immunodeficient (SCID) mice. The AML-CL and AML-PS lines were originated from leukemic blasts purified respectively from the peripheral blood of a 27-year-old woman with previously untreated hyperleukocytotic AML and from the bone marrow of a 61-year-old man during the third leukemic relapse. The 2 lines were maintained and serially transplanted i.p. in SCID mice. AML-PS and AML-CL produced ascitogenous gross tumors after approximately 4 and 6 weeks, respectively, and all mice died within 6-8 weeks. Microscopic evaluation of different organs at autopsy showed massive involvement of bone marrow, liver and spleen, though with differences in the tumor burdens for the 2 lines (AML-CL > AML-PS). Flow cytometric analysis documented the spread of leukemic cells to bone marrow, peripheral blood and spleen. AML-PS and AML-CL cells show an immunophenotypic profile (CD13+, CD33+) and cytogenetic findings similar to freshly isolated blasts. Interleukin-1β (IL-1β) gene expression was observed by Northern blot analysis in leukemic cells from AML-CL and AML-PS SCID mice. After 24 hr of culture both lines released IL-1β in culture supernatants. High levels of circulating IL-1β were secreted in plasma of tumor-bearing mice. This AML-SCID murine model could contribute to an understanding of the mechanisms of AML growth in vivo and the possible role of the autocrine production of IL-1β in promoting cell growth.
UR - http://www.scopus.com/inward/record.url?scp=0028923090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028923090&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910610223
DO - 10.1002/ijc.2910610223
M3 - Article
C2 - 7705959
AN - SCOPUS:0028923090
VL - 61
SP - 280
EP - 285
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 2
ER -